目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycystic Ovarian Syndrome - Overview
Polycystic Ovarian Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Ovarian Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
AbbVie Inc
Amaro Therapeutics Inc
Annji Pharmaceutical Co Ltd
Arkay Therapeutics LLC
Bayer AG
Besins Healthcare SA
BioRestorative Therapies Inc
EffRx Pharmaceuticals SA
Exeltis Pharmaceuticals Holding SL
Jiangsu Hengrui Medicine Co Ltd
Livzon Pharmaceutical Group Co Ltd
Spruce Biosciences Inc
Zydus Lifesciences Ltd
Polycystic Ovarian Syndrome - Drug Profiles
(celecoxib + metformin hydrochloride + valsartan) - Drug Profile
Product Description
Mechanism Of Action
(dienogest + ethinylestradiol) PR - Drug Profile
Product Description
Mechanism Of Action
ALZ-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug 1 for Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs to Agonize TAS2R1 for Polycystic Ovarian Syndrome (PCOS) - Drug Profile
Product Description
Mechanism Of Action
elagolix sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
follitropin alfa biosimilar - Drug Profile
Product Description
Mechanism Of Action
metformin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
progesterone - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein to Agonize PEDF for Women's Health - Drug Profile
Product Description
Mechanism Of Action
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHR-7280 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ThermoStem - Drug Profile
Product Description
Mechanism Of Action
History of Events
tildacerfont - Drug Profile
Product Description
Mechanism Of Action
History of Events
Polycystic Ovarian Syndrome - Dormant Projects
Polycystic Ovarian Syndrome - Discontinued Products
Polycystic Ovarian Syndrome - Product Development Milestones
Featured News & Press Releases
Sep 10, 2021: Livzon Pharmaceutical Group announcement on obtaining approval notice for clinical trial on a drug
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Polycystic Ovarian Syndrome - Pipeline by AbbVie Inc, 2022
Polycystic Ovarian Syndrome - Pipeline by Amaro Therapeutics Inc, 2022
Polycystic Ovarian Syndrome - Pipeline by Annji Pharmaceutical Co Ltd, 2022
Polycystic Ovarian Syndrome - Pipeline by Arkay Therapeutics LLC, 2022
Polycystic Ovarian Syndrome - Pipeline by Bayer AG, 2022
Polycystic Ovarian Syndrome - Pipeline by Besins Healthcare SA, 2022
Polycystic Ovarian Syndrome - Pipeline by BioRestorative Therapies Inc, 2022
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals SA, 2022
Polycystic Ovarian Syndrome - Pipeline by Exeltis Pharmaceuticals Holding SL, 2022
Polycystic Ovarian Syndrome - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Polycystic Ovarian Syndrome - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Polycystic Ovarian Syndrome - Pipeline by Spruce Biosciences Inc, 2022
Polycystic Ovarian Syndrome - Pipeline by Zydus Lifesciences Ltd, 2022
Polycystic Ovarian Syndrome - Dormant Projects, 2022
Polycystic Ovarian Syndrome - Discontinued Products, 2022

List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022